Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lifirafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 20/20 | 1.00 |
| ▸ | RAF1 | P04049 | 17/20 | 1.00 |
| ▸ | ARAF | P10398 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lifirafenib SCHEMBL29464034 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL15085317 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL29749194 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL20133921 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL15085289 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL24916576 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL20129833 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL15085287 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL29750805 | 0.94 | BRAF (0.89) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL29750807 | 0.94 | BRAF (0.89) | BRAFRAF1ARAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4119559-A1 | MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | BeiGene, Ltd. (KY) | 2023-01-18 | — | — | EP | claimed |
| EP-3283486-B1 | MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | BEIGENE LTD (KY) | 2022-07-27 | — | — | EP | claimed |
| CN-113307805-A | Maleate salts of B-RAF kinase inhibitors, crystalline forms, processes for their preparation and their use | 百济神州有限公司 | 2021-08-27 | — | — | CN | claimed |
| CN-107531682-B | Maleate salts of B-RAF kinase inhibitors, crystalline forms, processes for their preparation and their use | 百济神州有限公司 | 2021-05-04 | — | — | CN | claimed |
| US-10351559-B2 | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore | BEIGENE, LTD. (KY) | 2019-07-16 | — | — | US | claimed |
| US-20190170752-A1 | METHOD FOR PREDICTING EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN CANCER PATIENTS | BEIGENE, LTD. (KY) | 2019-06-06 | — | — | US | claimed |
| US-20180127412-A1 | MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | BEONE MEDICINES I GMBH (CH) | 2018-05-10 | — | — | US | claimed |
| EP-3402822-B1 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | GENMAB AS (DK) | 2025-03-12 | — | — | EP | disclosed |
| EP-4125842-B1 | CO-ADMINISTRATION OF MIRDAMETINIB AND LIFIRAFENIB FOR USE IN TREATING CANCERS | BEIGENE LTD (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023212071-A1 | COMBINATION AND THE USE THEREOF | BEIGENE SWITZERLAND GMBH (CH) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209611-A1 | METHODS OF TREATING CANCER WITH A B-RAF INHIBITOR, IN PARTICULAR LIFIRAFENIB | BEIGENE SWITZERLAND GMBH (CH) | 2023-11-02 | — | — | WO | disclosed |
| US-20230321261-A1 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-10-12 | — | — | US | disclosed |
| WO-2023076991-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-2797888-B1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE LTD (KY) | 2016-06-08 | — | — | EP | disclosed |
| US-9273046-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2016-03-01 | — | — | US | disclosed |
| US-9273046-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2016-03-01 | — | — | US | disclosed |
| US-9273046-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2016-03-01 | — | — | US | disclosed |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2015-02-12 | — | — | US | disclosed |
| WO-2013097224-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351559-B2 | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore | BRAF, RAF1, NRAS | BRAF 1/4885RAF1 2/4885ARAF 6/4885 |
| US-20190170752-A1 | METHOD FOR PREDICTING EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN CANCER PATIENTS | CD274, PDCD1LG2, PDCD1 | BRAF 171/4885RAF1 1014/4885ARAF 1012/4885 |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885ARAF 3/4885 |
| US-20230321261-A1 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | AXL, BRAF, MAPK1 | BRAF 2/4885RAF1 72/4885ARAF 55/4885 |
| US-20180127412-A1 | MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | BRAF, RAF1, NRAS | BRAF 1/4885RAF1 2/4885ARAF 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.